Tariffs Knock Down Arm Stock. Should Investors Buy the Dip?
End-market demand for smartphones could take a big hit, hurting Arm's royalty revenue.
A sky-high valuation adds to the risks.
10 stocks we like better than Arm Holdings ›
Arm Holdings (NASDAQ: ARM) spooked investors this week by declining to offer an outlook for fiscal 2026, which kicked off in April, along with its quarterly report. Arm cited uncertainty surrounding U.S. tariff policy for the cautious stance.
Arm's intellectual property and technology are pervasive across the semiconductor industry. Arm-based chips reign supreme in the smartphone, microcontroller, and embedded markets, and they're making inroads in PCs and servers as well. The explosion in artificial intelligence (AI) infrastructure spending is a boon, and increasing chip complexity, coupled with rising demand for custom chips, is pushing up royalty rates.
While Arm has plenty of visibility into its licensing pipeline, the company can't predict end-market demand. Arm earns royalties for each device shipped that uses its technology, so the volume of Arm-powered devices is the main driver of royalty revenue. Arm generates higher royalties for more complex chips, like server CPUs, and lower royalties for simpler chips like microcontrollers.
With Arm's outlook uncertain and the stock well off its all-time high, should investors buy the dip or stay away?
The smartphone market is critical for Arm. An Arm-powered chip is at the heart of essentially every iPhone and Android device that ships. In 2024, IDC estimates that global smartphone shipments grew 6.4% to 1.24 billion.
While smartphones are currently exempt from the worst of the U.S. tariffs on Chinese imports, the situation could change at any time. As it stands today, Apple expects tariffs to add around $900 million in costs in the current quarter, even as the company races to use non-Chinese manufacturing partners to source U.S.-bound iPhones. Smartphone prices in the U.S. could rise if Apple and its competitors pass off those higher costs to consumers, and they could rise further if a higher tariff rate is eventually put in place.
More expensive smartphones would likely knock down demand, leading consumers to hold on to their old phones for longer. If smartphone prices were rising in a vacuum, the hit to Arm would be small. Unfortunately, that's not the case. The prices of a wide range of products are likely to rise in the U.S. under the current tariff regime, and prices will spike further if the delayed reciprocal tariffs are allowed to go into effect.
While the timing and severity are up in the air, a recession in the U.S. is a real possibility. Downturns or recessions in other global economies, triggered by a drop in exports to the U.S., are a possibility as well. Weakness in the smartphone market could extend well beyond the U.S. if the impact of tariffs cascades in such a manner.
Outside of smartphones, Arm's push into PCs and servers could be stunted by slumping demand. The PC market would likely take a similar hit as the smartphone market under the worst-case scenario, with prices rising and end users holding on to devices for longer. In the server market, any slowdown in data center investment activity would hurt Arm's effort to grow its server CPU business.
In the long run, Arm will almost certainly remain dominant in its core markets and continue to gain ground elsewhere. In the short run, though, the company's results are anyone's guess.
One reason investors should be cautious, outside of the unprecedented level of uncertainty created by U.S. tariff policy, is Arm's valuation. The company is valued at around $125 billion, which puts the price-to-earnings ratio based on fiscal 2025 adjusted EPS well over 200. That's optimistic, to say the least.
While Arm's long-term growth story is still intact, the risks from U.S. tariffs, combined with a beyond-premium valuation, make the stock a risky bet.
Before you buy stock in Arm Holdings, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Arm Holdings wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $623,103!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $717,471!*
Now, it's worth noting Stock Advisor's total average return is 909% — a market-crushing outperformance compared to 162% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of May 5, 2025
Timothy Green has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Apple. The Motley Fool has a disclosure policy.
Tariffs Knock Down Arm Stock. Should Investors Buy the Dip? was originally published by The Motley Fool

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Movano Health Plans to Timely Request a Hearing Before a Nasdaq Hearings Panel
Received Delisting Notice from Nasdaq Related to Minimum Bid Price Requirement and Late Filing of the Form 10-Q for the period ended March 31, 2025 PLEASANTON, Calif., July 11, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) (the "Company") announced today that, on July 7, 2025, it received a delisting determination from The Nasdaq Capital Market with respect to the $1.00 per share bid price requirement (the "Bid Price Requirement"), as set forth in Listing Rule 5550(a)(2), and the late filing requirement, as set forth in Listing Rule 5250(c)(1), given the delay in filing its Form 10-Q for the quarter ended March 31, 2025 (the "Filing Requirement")(together, the "Notice"). Accordingly, the Company plans to timely submit a request for a hearing before a Nasdaq Hearings Panel (the "Panel"). While the hearing request only stays suspension and delisting for 22 calendar days from the date of the Notice, the Company intends to request an extended stay, concurrent with the filing of the hearing request through the conclusion of the hearings process and the expiration of any exception period granted by the Panel following the hearing. On July 7, 2025, the Company received the Notice from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that because the closing bid price for the Company's common stock had fallen below $1.00 per share for 30 consecutive trading days, the Company was no longer in compliance with the Bid Price Requirement. Pursuant to Listing Rule 5810(c)(3)(A)(iv), the Company was not eligible for any compliance period specified in Rule 5810(c)(3)(A) due to the fact that the Company has effected a reverse stock split over the prior one-year period. As noted above, the Company plans to submit a request for an extended stay through the conclusion of the hearings process; however there can be no assurance that the Panel will grant the Company's extended stay request or the Company's request for continued listing or that the Company will be able to regain compliance and thereafter maintain its listing on Nasdaq. About Movano Health Founded in 2018, Movano Inc. (Nasdaq: MOVE) dba Movano Health is developing a suite of purpose-driven healthcare solutions to bring medical-grade data to the forefront of wearables. Featuring modern and flexible form factors, Movano Health's devices offer an innovative approach to delivering trusted data to both customers and enterprises, capturing a comprehensive picture of an individual's health data and uniquely translating it into personalized and intelligent insights. Movano Health's proprietary technologies and wearable medical device solutions enable the use of data as a tool to proactively monitor and manage health outcomes across a number of patient populations that exist in healthcare. For more information on Movano Health, visit Forward Looking Statements This press release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements relating to the Company's intentions to request an extended stay of suspension from listing or appeal Nasdaq's delisting determination. Actual results could differ materially from those expressed in or implied by the forward-looking statements due to a number of risks and uncertainties, including but not limited to our ability to cure any deficiencies in compliance with the Bid Price Requirement and Nasdaq's requirements related to the timely filing of periodic financial reports or maintain compliance with other Nasdaq Listing Rules; our ability to ultimately obtain relief or extended periods to regain compliance from Nasdaq, if necessary, or to meet applicable Nasdaq requirements for any such relief or extension; and risks related to the substantial costs and diversion of personnel's attention and resources due to these matters. Delisting from Nasdaq would materially and adversely affect our ability to raise capital and our financial condition and business. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. View original content to download multimedia: SOURCE Movano Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Yahoo
12 minutes ago
- Yahoo
Newly Elected Directors of Sinovac Hold the First Board Meeting
Mr. Andrew Y. Yan elected Chairman of the Board New Board Unanimously Resolved to Explore Future Dividend Plans, Conduct Search for New Auditor for Resuming NASDAQ Trading, and Restore Stable Operations of the Company, Amongst Other Things BEIJING, July 10, 2025--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced the new board of directors of the Company (the Board), comprising Mr. Simon Anderson, Mr. Shan Fu, Mr. Shuge Jiao, Mr. Chiang Li, Mr. Yuk Lam Lo, Mr. Yumin Qiu, Mr. Yu Wang, Ms. Rui-Ping Xiao, Mr. Andrew Y. Yan and Mr. Yin Weidong (collectively, the new Directors), held its first meeting today at the Company's headquarters in Beijing. This meeting is the first Board meeting held after the new Directors were elected to the Board at the Special Meeting of the Company held on July 8, 2025, at 8:00 p.m. Atlantic Standard Time. At the Special Meeting, 33,248,861 votes (or 54.71% of the total votes present and voting at the Special Meeting) were voted in favor of the election of the new Directors. The meeting was attended by eight of the ten new Directors, and another new Director who was absent from the meeting due to a schedule conflict expressed his support for the Board. As the first item on the agenda, the Directors elected Mr. Andrew Y. Yan, Managing Partner of SAIF Partners, as the Chairman of the Board. Throughout the meeting, the Board stressed its unwavering commitment to shareholder value creation and its intent to explore future dividend plans. Further, as the first steps to rectify the disruptions and chaos created by the previous board of the Company, the Board unanimously resolved that it will work diligently with the management and the advisors of the Company to appoint a new auditor of the Company so that the trading of the Company's shares on NASDAQ can be resumed as soon as possible, to properly and legally resolve the Company's ongoing litigations with shareholders, and to take necessary steps to defend the election results of the Special Meeting and restore stable operations of the Company. To this end, the Board declared that no individual or entity shall be entitled to represent the Company unless they are properly authorized by the Board or the management. At the meeting, the Board confirmed that Mr. Yin Weidong shall continue to serve as Executive Director and Chief Executive Officer of the Company. The Board thanked the current management for their extraordinary efforts in the past few years in navigating the Company through various challenges and confirmed its support of the current management to continue to lead the Company. Mr. Yin Weidong thanked the Board for its trust and expressed his confidence in the Company under the leadership of the Board. Mr. Andrew Y. Yan, Chairman of the SINOVAC Board, commented, "I am honored to be elected Chairman at this pivotal moment in SINOVAC's journey. With the support of our new Board, which fairly represents all shareholders' interest, we are committed to rebuilding trust, enhancing transparency, and delivering long-term value to our shareholders. This marks the beginning of a new era for the Company—one grounded in sound governance, operational excellence, and global ambition. I am confident that, together with management, we will lead SINOVAC into a stronger, more sustainable future." About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. Such statements are based upon current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's or Board's control, which may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company and Board do not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law. View source version on Contacts Investor and Media Contact Sinovac Biotech ir@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Forbes
an hour ago
- Forbes
Apple Prepares To Delay The Next MacBook Pro
New MacBook Pro laptops are displayed during Apple's Worldwide Developers Conference 2023 (Photo by ... More JOSH EDELSON/AFP via Getty Images) Apple is on course to release the new iPhone 17 family in September, but the outlook for MacBook Air and MacBook Pro fans is not as rosy. Apple looks to have delayed the release of the new macOS hardware into 2026. MacBook Pro Launch Date Details The new date comes from Bloomberg's Mark Gurman. Reporting on Apple's upcoming portfolio (including the long-suspected iPhone 17e), he notes that the upgraded MacBook Pro and MacBook Air laptops may not arrive until 2026. Until now, the expectation has been that Apple would introduce the M5 —the next desktop classic Apple Silicon chipset—before the end of the year with new versions of the iPad Pro and MacBook Pro. This would be a similar path to the release of the Apple Silicon M4 last year, but not identical. The M4 was launched ahead of Apple's Worldwide Developer Conference in May 2024 and debuted inside the seventh generation of the iPad Pro almost immediately. That was followed in the fall with the M4 MacBook Pro, MacBook Pro Max and MacBook Pro Max. Delaying The MacBook Pro The Apple Silicon M5 has yet to show up in 2025. The Worldwide Developer Conference came and went with nary a sight of the new silicon. Neither has the next iPad Pro or the MacBook Pro. Many have been looking at the traditional October dates for the release of the MacBook M5 family, potentially with the iPad Pro arriving at the same time. Gurman's report pushes back this launch date into 2026. Apple has taken this route before, with the MacBook Pro M2 pushed back into January 2023. Unlike the iPhone, which has an almost mythical need to launch in the second week in September. Arguably, that's linked to the one-year contracts provided by networks, and there's no such historical support for buying laptops and desktops. Keeping The MacBook Pro On An Annual Schedule That gives Apple a little bit more of a cushion ot get things right rather than follow a strict schedule, at least for hardware. The annual updates across the operating systems does refresh the ecosystem every twelve months. With the increased demand for artificial intelligence and Apple's push to process as much data locally, the demands on computing power are climbing ever upwards. In part, that demand is driving the update. It may not be as traditional as the locked-in September date, but with the operating system on an annual update cycle, and the Apple Silicon chipsets on a similar schedule, annual updates of the Mac hardware are inevitable. Now read the latest MacBook Pro, iPhone, and Apple news in Forbes' weekly news digest...